FDA Reports Two Deaths Linked to Illicit Retatrutide

Key points

• The FDA received two adverse event reports in 2026 alleging deaths from unapproved retatrutide: one in July involving a 41-year-old woman and another in September involving a 49-year-old patient.
• The July report described a cardiac arrest in a woman who obtained the drug from an 'unreliable source,' while the September report involved a patient who purchased vials from a vendor named AlphaLabs after a licensed nurse recommended them.
• Eli Lilly, the developer of retatrutide, stated that the deaths involved 'black-market' products containing incorrect active ingredients or contaminants, and the company is taking legal action against bootleg sellers.
• The FDA declined to verify the specific details of the reports but noted that it reviews adverse events to monitor safety, while CBS News could not independently confirm the information due to redactions.
• Poison centers have seen a steady rise in reported exposures to retatrutide, with 862 cases logged in the three months ending in September 2026, up from 249 in the first quarter of the year.

Background

Retatrutide is an experimental weight-loss drug developed by Eli Lilly that has shown superior efficacy in clinical trials compared to existing market leaders. However, it has not received FDA approval, meaning its commercial sale is illegal. Previous coverage noted that GLP-1 receptor agonists, a class of drugs retatrutide belongs to, are associated with side effects like hair loss and nail detachment, though causation remains debated. The current situation highlights the dangers of an unregulated market for these high-demand medications, where third-party certifications and 'research use only' labels are often misused to create a false sense of legitimacy.

How outlets are covering it

CBS News emphasizes the potential dangers of the illicit market and the lack of medical supervision, citing Harvard Medical School professor Pieter Cohen who criticized the FDA for not aggressively investigating the cases. Eli Lilly focuses on the integrity of its product, stating that the deaths were caused by 'black-market' versions with wrong ingredients or contaminants, and is pursuing legal action to protect its brand. The attorney for AlphaLabs, the vendor named in the September report, argued that the redacted FDA report lacked sufficient evidence to link her client to the sale, noting that the vial image did not match current packaging and that no batch numbers were provided. She also expressed concern over the licensed nurse's role in recommending a 'research use only' product to a patient.

Why it matters

These reported deaths underscore the risks of the growing black market for unapproved weight-loss drugs. As demand for effective obesity treatments rises, patients are increasingly turning to unregulated vendors, bypassing the FDA's safety approval process. This not only endangers individual patients but also undermines public trust in legitimate pharmaceutical developments, as adverse reactions to counterfeit products may be wrongly attributed to approved medications.

What to watch

Eli Lilly is pursuing legal action against companies selling bootleg versions of retatrutide. The FDA is reviewing the adverse event reports but has not confirmed the details or announced specific enforcement actions. The attorney for AlphaLabs has called for a review of the licensed nurse involved in the September case. Consumers are advised to avoid unapproved weight-loss drugs and to look for credible third-party certifications for any supplements they use.